Posted by Michael Wonder on 17 Dec 2020
Kite’s Tecartus (KTE-X19) granted conditional marketing authorisation for the treatment of relapsed or refractory mantle cell lymphoma in Europe
16 December 2020 - 93% of patients in ZUMA-2 pivotal trial responded to single infusion of Tecartus.
Kite, a Gilead Company, today announced that the European Commission has granted conditional marketing authorisation for Tecartus (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19).
Tecartus is a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.
